Dr Suchitra Sundaram describes critical disparities in DLBCL treatment, urging for equitable access to care and representation in clinical trials.
Assistant Professor, Department of Hematology and Medical Oncology, Mount Sinai Icahn School of Medicine; Staff Physician, Department of Hematology and Medical Oncology, Mount Sinai Hospital, New York, NYServe as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech; Curio Science
Serve as a speaker or a member of a speakers bureau for: Leukemia Lymphoma Society; Lymphoma Research Foundation; Dava Oncology; Takeda , which arise from a complex interaction of factors including demographics, socioeconomic status, and access to quality healthcare. Dr Sundaram notes that Black patients present at a younger age and have consistently lower survival rates compared with White patients, underscoring the need for further validation of these findings in larger studies.
Additionally, underinsured patients often face more advanced disease stages and comorbidities, complicating their treatment outcomes. Dr Sundaram advocates for increased minority representation in clinical trials and improved access to novel therapies to address these disparities and ensure equitable care for all patients with DLBCL.Comments on Medscape are moderated and should be professional in tone and on topic.
Diffuse Large B-Cell Lymphoma Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies Single-Blind Study Single-Blind Studies B-Cell Lymphoma Healthcare And Medical Technology Health And Medical Tech Health And Med Tech Health And Medical Technology Healthcare Technology Medical Technology Lymphoma
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Treatment Offers Relief for Patients with Treatment-Resistant HypertensionThis news article highlights a new treatment option called renal denervation that offers hope for patients struggling with high blood pressure that doesn't respond to traditional medications. It tells the story of Michael Garrity, a patient whose severe hypertension was finally controlled after undergoing this procedure. It also discusses the potential benefits and limitations of renal denervation, as well as the need for further research and wider adoption.
Read more »
Johnson & Johnson's Spravato Approved as Standalone Treatment for Treatment-Resistant DepressionThe Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato, as the first standalone therapy for treatment-resistant depression. This marks a significant advancement in treating individuals whose depression symptoms haven't responded to at least two standard treatments. Spravato, previously approved for use alongside oral antidepressants, has shown promising results in relieving symptoms rapidly and durably.
Read more »
Johnson & Johnson's Nasal Spray Spravato Approved as Standalone Treatment for Treatment-Resistant DepressionThe FDA approved Johnson & Johnson's Spravato nasal spray as the first-ever standalone therapy for treatment-resistant depression, offering new hope for millions suffering from this challenging condition.
Read more »
FDA Approves First Standalone Treatment for Treatment-Resistant DepressionJohnson & Johnson's ketamine-derived nasal spray, Spravato, receives FDA approval as the first and only monotherapy for adults with major depressive disorder who haven't responded to oral antidepressants.
Read more »
Spravato Approved as Standalone Treatment for Treatment-Resistant DepressionJohnson & Johnson's Spravato (esketamine) receives expanded approval as a monotherapy for patients with depression who have not responded adequately to at least two antidepressant medications.
Read more »
Social Security Fairness Act Eliminates Benefit Disparities, But Raises Concerns About FundingThe Social Security Fairness Act aims to rectify long-standing inequities in Social Security benefits by removing the Government Pension Offset and Windfall Elimination Provision. While these changes will boost monthly payments for many recipients, they also raise concerns about the sustainability of Social Security Trust Funds.
Read more »